Add to ORKGRecommends ways for government, nonprofits, and academic institutions to work with the private sector to develop drugs and bring them to market more efficiently, including establishing models for intellectual property and technology transfer processes
Discovering new uses for drugs that are already on the market seems like it ought to be the low-lyin...
Every year, hundreds of promising basic discoveries in the pharmacological field are lost and will n...
Academic institutions are a well-established source of pharmaceutical innovation. However, the resea...
Over the past 25 years both the quality and quantity of pharmaceutical and biopharmaceutical researc...
Thesis: S.M. in Technology and Policy, Massachusetts Institute of Technology, School of Engineering,...
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.Includes bibliographical...
The roles of government, industry, and academia in science research have been recast repeatedly sinc...
Outlines how focusing on subpopulations with biomarkers could make the pre-clinical and clinical pha...
With the ever-changing landscape of translational research, the medical device and pharmaceutical in...
Big pharma is increasingly looking to academia for new drug leads and technologies; meanwhile univer...
The rate of new drug approvals in the US has remained essentially constant since 1950, while the cos...
Summary: The drug discovery and the drug development processes represent a con-tinuum of recursive a...
The need for novel diagnostic and therapeutic drugs with the potential to combat increasingly preval...
Academic-industry partnerships in biopharmaceuticals have been commonly arranged through firms licen...
The innovation process for novel medical therapies needs repair. The United States spends more than ...
Discovering new uses for drugs that are already on the market seems like it ought to be the low-lyin...
Every year, hundreds of promising basic discoveries in the pharmacological field are lost and will n...
Academic institutions are a well-established source of pharmaceutical innovation. However, the resea...
Over the past 25 years both the quality and quantity of pharmaceutical and biopharmaceutical researc...
Thesis: S.M. in Technology and Policy, Massachusetts Institute of Technology, School of Engineering,...
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.Includes bibliographical...
The roles of government, industry, and academia in science research have been recast repeatedly sinc...
Outlines how focusing on subpopulations with biomarkers could make the pre-clinical and clinical pha...
With the ever-changing landscape of translational research, the medical device and pharmaceutical in...
Big pharma is increasingly looking to academia for new drug leads and technologies; meanwhile univer...
The rate of new drug approvals in the US has remained essentially constant since 1950, while the cos...
Summary: The drug discovery and the drug development processes represent a con-tinuum of recursive a...
The need for novel diagnostic and therapeutic drugs with the potential to combat increasingly preval...
Academic-industry partnerships in biopharmaceuticals have been commonly arranged through firms licen...
The innovation process for novel medical therapies needs repair. The United States spends more than ...
Discovering new uses for drugs that are already on the market seems like it ought to be the low-lyin...
Every year, hundreds of promising basic discoveries in the pharmacological field are lost and will n...
Academic institutions are a well-established source of pharmaceutical innovation. However, the resea...